Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
2.510
+0.110 (4.58%)
Feb 4, 2025, 4:00 PM EST - Market closed
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Aclaris Therapeutics stock have an average target of 11, with a low estimate of 7.00 and a high estimate of 20. The average target predicts an increase of 338.25% from the current stock price of 2.51.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 23, 2024.
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 5 | 5 | 5 | 2 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $20 | Hold → Strong Buy | Upgrades | $20 | +696.81% | Dec 23, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $2 → $7 | Hold → Buy | Upgrades | $2 → $7 | +178.88% | Nov 19, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $2 → $7 | Hold → Strong Buy | Upgrades | $2 → $7 | +178.88% | Nov 19, 2024 |
| BTIG | BTIG | Hold → Strong Buy Upgrades $8 | Hold → Strong Buy | Upgrades | $8 | +218.73% | Nov 19, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $3 → $13 | Hold → Buy | Upgrades | $3 → $13 | +417.93% | Nov 18, 2024 |
Financial Forecast
Revenue This Year
11.84M
from 31.25M
Decreased by -62.10%
Revenue Next Year
9.77M
from 11.84M
Decreased by -17.50%
EPS This Year
-0.74
from -1.27
EPS Next Year
-0.54
from -0.74
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 14.6M | 20.9M | 22.9M | |||
| Avg | 11.8M | 9.8M | 8.5M | |||
| Low | 9.9M | 2.5M | 2.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -53.3% | 76.4% | 134.3% | |||
| Avg | -62.1% | -17.5% | -13.4% | |||
| Low | -68.2% | -78.7% | -74.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.33 | -0.16 | -0.50 | |||
| Avg | -0.74 | -0.54 | -0.66 | |||
| Low | -1.11 | -0.96 | -0.91 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.